Ricky Sharma MA MRCP FRCR PhD
- Cancer and Haematology
- Cell and Molecular Biology
- Dr. Stephanie Hatch, Laboratory Manager
- Dr. Rebecca Carter, Daphne Jackson Trust Fellow
- Dr. Nils Nicolay, Clinical Research Fellow
- Dr Esme Hill, Clinical Research Fellow
- Nida Sadique, DPhil Student
- Dr. Thomas MacGregor, Clinical Research Fellow
- Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, and Helleday T (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells Cancer Res, 70(13):5389-98.
- Issaeva N, Thomas H D, Pedley N, Djurenovic T, Kyle S, Zur R, Sleeth J, Stoimenov I, Chatzakos V, Mulligan E, Lundin C, Gubanova E, Harris A L, Sharma R A, Zdzienicka M Z, Curtin N J, and Helleday T (2010) 6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor and cisplatin resistance Cancer Res, 70(15):6268-76.
- Yang J, Parsons J, Nicolay NH, Caporali S, Harrington CF, Singh R, Finch D, D'Atri S, Farmer PB, Johnston PG, McKenna WG, Dianov G, and Sharma RA (2010) Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy Oncogene, 29(3):463-468.
- Nicolay NH, Berry DP, and Sharma RA (2009) Liver metastases from colorectal cancer: role of radio-embolization with systemic therapy Nature Rev Clin Oncol, 6:687-697.
- Parsons JL, Tait PS, Finch D, Dianova IL, Edelmann MJ, Khoronenkova SV, Kessler BM, Sharma RA, McKenna WG, and Dianov GL (2009) Ubiquitin ligase ARF-BP1/Mule modulates base excision repair EMBO J 28:3207-15.
|Tel||+44 (0)1865 235209|
The aim of the DNA Adduct Repair Group is to characterise fundamental biological mechanisms involved in the repair of adducts formed by reactive oxygen species, radiotherapy and platinum chemotherapies. The ultimate goal of this research programme is to translate biochemical knowledge of adduct formation and repair into clinical studies of cancer prevention and treatment.
The group is currently focussed on the effects of platinum chemotherapies on DNA. These laboratory studies are ongoing in parallel with Dr Sharma’s clinical studies of oxaliplatin as a radiosensitiser in the treatment of liver metastases from colorectal cancer. In collaboration with Dr Grigory Dianov’s group, cellular pathways of excision repair are being characterised in preclinical models as potential targets for improving current cancer therapies.
The research programme is funded by the NIHR Biomedical Research Centre Oxford, Cancer Research UK, the UK Medical Research Council via the Daphne Jackson Trust, the Bobby Moore Fund of Cancer Research UK, Sirtex Medical Ltd. and the Higher Education Funding Council for England.
The FOXFIRE trial is now open for recruitment to find out more please click this link: FOXFIRE Newsletter
Dr. Sharma was appointed as Clinical Lead for the Thames Valley Cancer Research Network http://www.tvcn.nhs.uk/research/ in May 2010. TVCRN is part of the National Cancer Research Network (NCRN), which is part of the National Institute for Health Research (NIHR). Dr. Sharma's aim in this post is to improve the speed, quality and integration of research in the Thames Valley, ultimately resulting in improved care for patients with cancer in Berkshire, Buckinghamshire, Oxfordshire and Swindon.
2009 HEFCE Clinical Senior Lecturer, University of Oxford
2006 - 2009 Senior Fellow, University of Oxford
2007 - Honorary Consultant in Clinical Oncology, Oxford Radcliffe Hospitals
2004 – 2006 Senior Registrar, Royal Marsden Hospital, London
2001 – 2006 Honorary Lecturer, University of Leicester
1998 – 2001 Clinical Research Fellow and Honorary Registrar, MRC Toxicology Unit and University Hospitals of Leicester
Degrees and Qualifications
2005 Fellow, Royal College of Radiologists
2001 Doctor of Philosophy, University of Leicester
1998 Member, Royal College of Physicians
1996 Master of Arts, University of Cambridge
1994 Bachelor of Medicine and Chirurgia, University of Cambridge
1992 Bachelor of Arts, University of Cambridge